

Nutrition in Clinical Practice

An open labelled study to monitor the effect of an amino acid formula on symptom management in children with spinal muscular atrophy type 1: The SMAAF Pilot Study

Journal:	<i>Nutrition in Clinical Practice</i>
Manuscript ID	NCP-2022-07-266.R1
Manuscript Type:	Clinical Research
Keywords:	Enteral nutrition < Nutrition, Probiotics < Research and Diseases, Amino acids < Research and Diseases, Spinal Muscular Atrophy, Constipation
Abstract:	<p>Background: An increasing number of families of spinal muscular atrophy (SMA) children are incorporating an amino acid-based enteral formula into their child's feeding regimens. Other components of the amino acid-based formula include added carbohydrates, electrolytes, and probiotics. Due to insufficient evidenced based research regarding the efficacy of the formula clinicians are unable to prescribe or endorse. The aim was to assess the tolerability and safety of an adapted version of the traditional SMA amino acid formula (SMAAF) in children with SMA Type I.</p> <p>Methods: Children with SMA Type I were recruited if exclusively enterally fed and experiencing at least one gastrointestinal symptom (reflux, vomiting, constipation and/ or diarrhoea). Children were transferred on to an amino acid formula (Neocate® Syneo™- Nutricia) for eight weeks. Primary outcome was feed tolerance, measured weekly by telephone consultation to monitor gastrointestinal tolerance.</p> <p>Results: Fourteen children were recruited, mean age 4.1 years (1.2SD). The mean resting energy expenditure measured by indirect calorimetry was 51kcal/ kg (7SD). The most common gastrointestinal complaint prior to switching to SMAAF was constipation (n=12). Ten of the 12 children who reported constipation symptoms were prescribed stool softeners/laxatives daily and after 8 weeks on SMAAF, 8 of these 10 (80%) children reduced or discontinue stool softener/ laxatives. Parents reported an improvement with reflux symptoms in 4 out of 5 children whilst on SMAAF.</p> <p>Conclusion: Our pilot study suggests that children with SMA Type I who are displaying gastrointestinal symptoms, such as constipation and reflux may benefit from an amino acid formula.</p>

SCHOLARONE™
Manuscripts

Abstract

Background: An increasing number of families of spinal muscular atrophy (SMA) children are incorporating an amino acid-based enteral formula into their child's feeding regimens. Other components of the amino acid-based formula include added carbohydrates, electrolytes, and probiotics. Due to insufficient evidenced based research regarding the efficacy of the formula clinicians are unable to prescribe or endorse. The aim was to assess the tolerability and safety of an adapted version of the traditional SMA amino acid formula (SMAAF) in children with SMA Type I.

Methods: Children with SMA Type I were recruited if exclusively enterally fed and experiencing at least one gastrointestinal symptom (reflux, vomiting, constipation and/ or diarrhoea). Children were transferred on to an amino acid formula (Neocate® Syneo™- Nutricia) for eight weeks. Primary outcome was feed tolerance, measured weekly by telephone consultation to monitor gastrointestinal tolerance.

Results: Fourteen children were recruited, mean age 4.1 years (1.2-SD). The mean resting energy expenditure measured by indirect calorimetry was 51kcal/ kg (7-SD). The most common gastrointestinal complaint prior to switching to SMAAF was constipation (n=12). Ten of the 12 children who reported constipation symptoms were prescribed stool softeners/laxatives daily and after 8 weeks on SMAAF, 8 of these 10 (80%) children reduced or discontinue stool softener/ laxatives. Parents reported an improvements with reflux symptoms in 4 out of 5 children whilst on SMAAF.

Conclusion: Our pilot study suggests that children with SMA Type I who are displaying gastrointestinal symptoms, such as constipation and reflux may benefit from an amino acid formula.

BACKGROUND

Spinal muscular atrophy (SMA) is the most common genetic cause of mortality in infancy, SMA type I is the most severe form of the disease, accounting for approximately 60% of cases.¹ SMA is characterized by degeneration of brainstem and spinal cord motor neurons that lead to progressive muscle weakness and atrophy.² These neurological changes result in progressive swallowing, feeding and gastrointestinal complications as well as respiratory failure.³

Improvements in standards of care and the advent of new therapeutic approaches have resulted in improvements in survival and functional abilities in these patients, changing the course of the disease.^{4, 5} So far, most of the attention has been focused on survival and motor or respiratory outcome.^{6, 7} Despite feeding being one of the most important aspects in the care of SMA, less has been reported about the possible impact of nutrition in the management of children with SMA type I.⁸

Of note, previous studies have reported more generalised metabolic abnormalities in SMA such as altered fatty acid metabolism, hyperlipidaemia, hyperglycaemia, hyperglucagonemia, increased hepatic insulin sensitivity and glucose intolerance.⁹⁻¹¹ Interestingly, lipid metabolism and fatty acid oxidation defects have been reported in early studies of patients with SMA where increased esterified carnitine and reduced β -oxidation capacity were observed.¹² Such perturbations could directly lead to impaired hepatic function, which is supported by the report of more than one-third of autopsies of children with SMA reveal liver steatosis on post-mortem necropsy.¹³

Current standard of care recommendations highlight the importance of a multidisciplinary approach in the management of SMA Type I which, includes nutrition and feeding as key components.^{14, 15} Progressive muscle atrophy in children with SMA is accompanied with decreased lean body mass, increased fat mass as well as gastrointestinal symptoms such as gastro-oesophageal reflux disease and constipation.¹⁶ Typically, long term nutritional support in the form of a gastrostomy is recommended as soon as oral intake is compromised.¹⁷

1
2
3 Recent studies led by our team working on SMA animal models support an independent and adjuvant
4 role for nutrition in the absence of proactive respiratory care interventions.¹¹ Their data, and clinical
5 experience, suggest a critical role for nutrition on quality of life in children with SMA.¹⁸ The potential
6 benefit of the synergistic effect of a specialised SMA diet and a drug in the management of SMA have
7 been highlighted, which is highly relevant in the present therapeutic landscape.^{19, 20}

8
9
10
11
12
13
14
15 Current dietetic recommendations for children with SMA is based on individual tolerance.^{18, 21}

16
17 However, an increasing number of families of SMA children are incorporating amino acid based enteral
18 formulas into their child's feeding regimens. Originating from North America, the diet was designed
19 and initiated by a SMA parents in the hope of improving SMA symptoms in their child. The diet has
20 grown in popularity over the last few years following positive feedback from parents and individuals
21 living with SMA, mostly via social media outlets.

22
23
24
25
26
27
28
29 Characteristics of the traditional amino acid formula diet (<http://www.aadietinfo.com>) include high
30 carbohydrates, low fats, probiotics, vitamin D, co-enzyme Q10, branched-chain amino acid
31 supplementation and oral hydration solutions. Anecdotally, families have reported improvements in
32 their child's symptoms which are often associated with SMA including airway secretions,
33 drooling, respiratory infections, constipation, and gastroesophageal reflux. Additionally, quality of
34 sleep along with improvements in strength and stamina have also been reported to improve whilst
35 following the SMA amino acid diet.²² However, due to insufficient evidenced based research, clinicians
36 are unable to prescribe or endorse the SMA amino acid diet, particularly in relation to associated risks
37 between a high carbohydrate diet with hypertriglyceridemia^{23, 24} and non-alcoholic fatty liver
38 disease.^{25, 26}

39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
There is a need for a prospective clinical assessment to monitor the impact of an amino acid enteral
formula on the common gastrointestinal symptoms seen in SMA Type I. Working with SMA families,
we devised an adapted version of the traditional SMA amino acid diet. The proposed aim of this study
was to assess the tolerability and safety of an adapted version of the traditional SMA amino acid diet

1
2
3 that contains an amino acid-based formula with added probiotics and additional carbohydrates
4
5 (SMAAF).
6
7

8 **METHODS**

10 **Patients**

11
12
13
14 Children were recruited from our specialist tertiary neuromuscular SMA outpatient's clinic between
15
16 June 2021 to May 2022. The inclusion criteria: a diagnosis of SMA Type I; which meant infants were
17
18 aged over six months old; exclusively enterally fed via a feeding tube (meeting at least 90% of total
19
20 energy intake from enteral formula); and experiencing at least one gastrointestinal symptom including
21
22 (definitions outlined below). Exclusion criteria: children without SMA Type I; are meeting less than
23
24 90% of their total energy requirements from an enteral feeding tube.
25
26
27

28
29 The study was approved by the Health Research Authority, Integrated Research Application System
30
31 (IRAS) 21/WS/0074 IRAS 295489. Written informed consent in accordance with universal good clinical
32
33 practice guidelines in accordance with the ethical standards of the Helsinki declaration of 1975 was
34
35 obtained from all parents of participants after discussing the objectives, study design, risks and
36
37 benefits of participation before enrolment into our study.
38
39

40 **Procedure**

41
42
43 SMAAF was a single center prospective study. Recruited children were transferred on to an amino acid
44
45 formula - (Neocate[®] Syneo[™]- Nutricia), which contains 34% medium chain triglycerides, 50%
46
47 carbohydrate, probiotic-bifidobacterium, and prebiotic-fructo-oligosaccharide. SMAAD was followed
48
49 for eight weeks; after two weeks on SMAAF additional carbohydrates (using Maxijul[®] Super Soluble)
50
51 were planned to be supplemented to 60% total energy intake. At the end of the eight-week trial
52
53 children were to revert to their original enteral formula to compare gastrointestinal symptoms for
54
55 another 4 weeks. Families were provided with components of SMAAF and a prescriptive individual
56
57
58
59
60

1
2
3 feed recipe during their outpatient visit. [Table 1 highlights the difference in nutrient intake when](#)
4 [comparing the traditional amino acid formula with SMAAF](#)
5
6
7

8 Families had two in person meetings at baseline and week eight, with a telephone consultation at
9
10 week four and six to monitor feed tolerance in respect to esophageal reflux, stool consistency and
11
12 frequency ([Figure 1](#)). Parents were requested to report symptoms as either: improved, no change or
13
14 worsened.
15
16
17
18
19

20 DATA GATHERING

21 Anthropometric Measurements

22
23 Weight (kg) and length (cm) measurements were collected at baseline (before changing to SMAAF)
24
25 and on completion of the 8-week trial. All anthropometric measurements were collected during their
26
27 routine neuromuscular outpatient clinic by trained clinicians using standardized conventional criteria
28
29 and recognized measuring procedures.
30
31
32
33
34
35

36 Gastrointestinal Tolerance Monitoring

37
38 Stool consistency is a central component in the description of normal or altered bowel habit. Physical
39
40 examination of stool can be considered as a proxy measure for stool consistency and refers to the
41
42 shape and apparent texture of the stool, which can be assessed visually. Stool form scales are a
43
44 standardised and inexpensive method of classifying stool into a finite number of categories that can
45
46 be used by families and health care professionals. The Bristol Stool Scale is a visual stool form scale-
47
48 the ideal stool is generally type 3 or 4, easy to pass without being too watery. Type 1 or 2 indicates
49
50 constipation, whereas types 6 and 7 indicate loose stools.²⁷
51
52
53
54

55 Tolerance and details of stooling patterns were recorded by families in weekly diaries. Descriptions of
56
57 feed tolerance included the following variables:
58
59
60

1
2
3 Reflux - defined as parental observation of the passage of gastric contents into the oesophagus
4 causing regurgitation, possetting or vomiting, which leads to troublesome symptoms that affect daily
5 functioning²⁸; constipation – defined as Rome IV Criteria, less than three defecations a week/ painful
6 and hard stools²⁹; persistent loose stools - lasting longer than 14 days, consisting of more than one
7 loose stool a day.³⁰
8
9

15 Oral Mucus Secretion Monitoring

16
17 Manual mechanical insufflation–exsufflation (cough assist) is the primary mode of airway clearance
18 therapy performed by families. Families were asked to record in their weekly diaries the frequency
19 and duration of their airway clearance individualised program including oral suctioning and mouth
20 wiping for drooling.
21
22

27 Indirect Calorimetry Measurements

28
29 Indirect calorimetry was measured at baseline and planned to be repeated after eight-weeks on
30 SMAAD (refer to protocol deviation below) to measure resting energy expenditure (REE) and
31 respiratory quotient (RQ). An open-circuit ventilated-hood system calorimetric measurements were
32 made using a portable metabolic cart (Q-NRG+ RMR, COSMED). It measures resting oxygen
33 consumption (V_{O_2}), carbon dioxide production (V_{CO_2}), and respiratory quotient. REE was auto
34 calculated from these parameters using Weir equation. COSMED Indirect calorimetry was calibrated
35 monthly, using a 2-point calibration method based on two separate mixtures of known gas content.³¹
36
37

38 Indirect calorimetry was completed by either GOC or SQ, with an early morning measurement
39 (between 08:00 and 09:00) collected during the SMA outpatient day clinic, measured after an 8-h
40 overnight fast to eliminate nutrient thermogenesis. The children lay awake, supine on a bed in a
41 thermally neutral environment (24°C) and were distracted by a portable screen to watch cartoons.
42
43
44
45
46

56 Statistical Analysis

1
2
3 Continuous quantitative data was calculated as mean and standard deviation. Z scores of weight-for-
4 age and length-for-age, were computed based on UK-WHO growth data.^{32, 33 34} The standard Student
5
6 t-test was used to compare the weight mean Z scores before and after SMAAF. Analysis of variance
7
8 was used to compare resting energy expenditure between predictive energy equations and indirect
9
10 calorimetry. P value < 0.05 was required for statistical significance. Statistical analysis was performed
11
12 with SPSS software (version 23, IBM SPSS Statistics, Armonk, NY, USA)
13
14
15
16
17
18
19
20
21
22
23
24

25 **RESULTS**

26
27
28 Fourteen children were recruited from June 2021 to May 2022, with a mean age of 4.1 years (1.2 SD),
29 of which 64% were female. The mean WAZ at baseline was -0.7 (0.9SD). At recruitment, all 14 children
30
31 required manual mechanical insufflation–exsufflation at least twice a day, with 11 of 14 (78%)
32
33 requiring non-invasive ventilation - biphasic positive airway pressure for at least 12 hours. All children
34
35 were receiving Nusinersen, an approved disease modifying treatment for SMA. Demographic
36
37 characteristics of the cohort can be found in Table 2.
38
39
40

41
42 Most children (50%; 7 of 14) were on a standard 1kcal/ ml whole protein enteral formula prior to
43
44 trialling SMAAF; whereas, 3 out of 14 (21%) were already on an amino acid formula (without
45
46 probiotics). A full breakdown of feed formulas can be seen in Table 2. Indirect Calorimetry was
47
48 measured at the start of the study to assess energy requirements and respiratory quotient. The mean
49
50 resting energy expenditure was 803 kcal (103 SD), which equated to 51.5 kcal/ kg (7 SD). The mean
51
52 respiratory quotient was 0.80 (0.05 SD) (Table 3). An analysis of variance was used to compare resting
53
54 energy requirements between indirect calorimetry measurements and predictive energy equations
55
56 (Schofield equation³⁵ and Spinal muscular atrophy equation³¹) there was no significant difference
57
58
59
60

1
2
3 between values, p value 0.7 and 0.6, respectively (Table 3). A breakdown of key nutritional
4 components of children on SMAAF can be viewed in Table 4.
5
6
7

8 The most common gastrointestinal complaint reported prior to switching to SMAAF was constipation,
9 present in 12 of 14 (85%) children, of which 10 of the 12 (83%) children required daily stool
10 softeners/laxatives were used to help regulate bowel function. Reflux was reported in 5 of 14 (35%)
11 children (Table 4). Within one week of switching to SMAAF families reported a significant
12 improvement in constipation symptoms.
13
14
15
16
17
18
19

20 Eight of the 10 (80%) children who received stool softeners/laxatives saw an improvement in
21 constipation symptoms and either stopped or reduced medication (from daily to prescribed as
22 required). All three children who were previously on standard amino acid formula prior to switch to
23 amino acid formula with added pre and probiotics reported an improvement in stool consistency and
24 frequency.
25
26
27
28
29
30
31

32 Stool consistency (as per Bristol stool chart classification) significantly improved from baseline
33 compared to end of study (week 8) in children who switched to SMAAF; 2.2 (0.4SD) vs 3.6 (0.4SD) p<
34 0.001; CI 2.72-3.72, respectively. Similarly, stool frequency (bowel movements per week) increased
35 from baseline compared to end of study (week 8) from 3.6 (1.08SD) vs 4.9 (0.45SD) per week; p< 0.09,
36 CI -0.65-2, respectively.
37
38
39
40
41
42
43

44 Improvements in reflux was seen in 4 of 5 (80%) children, and a reduction in oral secretion was
45 reported in 6 of 14 (43%) children (Table 5). Although parents reported a reduction in reflux and oral
46 secretion in respect to mouth wiping or mucus volume suctioned whilst receiving SMAAF, this was not
47 captured in parent diaries and warrants further discussion how best to capture this outcome
48
49
50
51
52
53

54 Appropriate weight gain was observed while children were following SMAAF for the eight-week trial
55 (baseline WAZ score: -0.7 [0.9 SD] vs 8-weeks -0.5 [0.7 SD], p=.03).
56
57
58

59 **Adverse Events and Amendments to original protocol**

60

1
2
3 No participants experienced any serious adverse events. However, due to improved gastrointestinal
4 symptoms within one week of starting SMAAF, only two families chose to add additional
5 carbohydrates. Therefore, indirect calorimetry was not repeated at the end of the eight-week trial as
6
7 there was no change in macronutrient intake. Furthermore, 12 of the 14 families refused to revert to
8 their original feed formula after the eight-week trial. The two families who did revert to their previous
9
10 formula reported resumption of constipation within one week and requested to restart SMAAF. An
11
12 Amendment category C was submitted to the Health Research Authority to report changes to the
13
14 original protocol: 295489 21SH01-2 17 Jan 2022 reference 143229.
15
16
17
18
19
20
21

22 **DISCUSSION**

23
24 With the development of disease modifying treatments children with [SMA Type I are living beyond](#)
25 [the previous four to five years life expectancy](#) but continue to be affected by the highest disease
26
27 burden. Our pilot study suggests that children with SMA Type I who are displaying gastrointestinal
28
29 symptoms, especially when constipation is as a key feature of their clinical phenotype, may benefit
30
31 from an amino acid formula.
32
33
34

35
36 It has been reported that 43% of children with SMA Type I suffer from severe constipation, with
37
38 abdominal pain and meteorism reported in 15% and 14%, respectively³⁶. This is significantly higher
39
40 when compared to childhood constipation in the general population, which ranges from 0.7% to 29.6%
41
42 (median 8.9; inter quartile range 5.3–17.4).³⁷ SMAAF, our simplified version of the traditional SMA
43
44 amino acid diet had the most significant impact in children who suffered from constipation and
45
46 required daily medication to regulate their bowel functions.
47
48
49

50
51 The cause of chronic constipation in children with SMA Type I is multifactorial, including reduced
52
53 intake of fibre and fluids, gastrointestinal dysmotility related to a reduced tone and impaired strength
54
55 of abdominal wall muscles.³⁸ Additionally, animal studies have also reported morphological (both
56
57 gross and microscopic structural) changes within the gastrointestinal tract, along with alterations with
58
59
60

1
2
3 the enteric nervous system, resulting in inflammation and subsequent macrophage infiltration of the
4
5 small intestine.³⁹
6
7

8 Our study found an improvement in bowel function and cessation or reduction of constipation related
9 medication in children who commenced SMAAD. Our findings are not only supported by the anecdotal
10 reports from families but also by Bach et al. (2007) who performed a retrospective chart review and
11 caregiver questionnaire on 103 families of children with SMA Type I. Of which, 57 children were on a
12 modified amino acid diet, supplemented with B vitamins and minerals, glutamine, carnitine, long-
13 chained free fatty acids, and probiotics - Lactobacillus. All the parents of the children using the
14 modified amino acid diet reported one or more of the following benefits: decreased abdominal
15 distention and constipation, improved oral secretions and reduced perspiration.⁴⁰
16
17
18
19
20
21
22
23
24
25
26

27 Of consideration, an additional factor that may be contributing to constipation in SMA Type I is the
28 chronic and ubiquitous use of prophylactic antibiotics in our cohort; prescribed to protect against
29 opportunistic lung infections. Broad-spectrum antibiotics can affect the abundances of 30% of the
30 bacteria in the gut community, causing rapid and significant drops in taxonomic richness, diversity,
31 and evenness⁴¹. The routine practice of prophylactic antibiotic administration alters gut flora causing
32 dysbiosis and may be contributing to the gastrointestinal complications seen in SMA Type I.^{42, 43}
33 Parents of children with SMA Type I have been adding probiotics to their child's amino acid diet to
34 overcome the side effects of broad-spectrum antibiotics.⁴⁰
35
36
37
38
39
40
41
42
43
44

45 A controversial component of the traditional SMA amino acid diet is its excessively high carbohydrate
46 intake. The high carbohydrate and low-fat composition of the diet is hypothesised to be beneficial for
47 children with SMA Type I by re-balancing the aberrant glucose levels, most likely caused by insufficient
48 glycogen storage due to reduced muscle mass. Thus, a diet high in carbohydrate is thought to prevent
49 hypoglycaemia.⁴⁴ Furthermore, the low-fat content can help with gastric motility and emptying which
50 will reduce reflux.⁴⁵ However, excess glucose within the body is converted to triglycerides and stored
51 as fat, contributing to total fat mass and hypertriglycaemia.²⁴ Of note, this practice of excessive
52
53
54
55
56
57
58
59
60

1
2
3 glucose intake may increase the risk of developing a fatty liver, a complication already seen in children
4
5 with SMA.¹³ Furthermore, the addition of carbohydrate module will add to the osmolality which may
6
7 impact stool consistency and frequency⁴⁶
8
9

10 Children with SMA have an inherent underlying liver abnormality, possibly due to abnormal fatty acid
11
12 metabolism, and decreased stores of glutathione.⁹ The exact mechanism of this fatty acid metabolism
13
14 abnormality in SMA is unknown, but it is suspected to be related to loss of survival motor neuron
15
16 function, correlates with severity of SMA, and is not directly related to a known genetic disorder of
17
18 mitochondrial fatty acid oxidation.²⁰
19
20

21
22 It appears that manipulating the type of fat in the diet may improve gastrointestinal symptoms and
23
24 dyslipidaemia.⁸ SMAAF contains 34% Medium Chain Triglycerides (MCTs), MCTs are more easily
25
26 absorbed into the bloodstream from the gastrointestinal tract, unlike most other lipid molecules that
27
28 require a complex process of digestion.⁴⁷ Dietary approaches aimed at modulating fatty acid
29
30 metabolism defects and their subsequent effects on whole-body metabolic health are therefore an
31
32 interesting strategy to improve quality of life of SMA patients.⁸
33
34

35
36 Further studies are needed to determine whether dietary manipulation used in mitochondrial long-
37
38 chain fatty acid oxidation disorders²² can also benefit children with SMA and ameliorate fatty liver
39
40 pathology. However, manipulating the diet without specialist dietetic input may result in nutritional
41
42 deficiencies as identified by Poruk et al., (2012) who monitored types of dietary intake and
43
44 supplementation in children with SMA Type 1 between the first and last visits. The average length of
45
46 time between the first and last visit was 18 months. The number of subjects following the traditional
47
48 SMA amino acid diet increased from the first visit from 18 of 47 (38%) to the last visit to 23 of 34 (68%).
49
50 The most common source of fat supplementation was safflower oil. Children in this study following an
51
52 amino acids diet had a substantially lower percentage of fat intake and thus, lower intake of essential
53
54 fatty acids. This may increase risk for essential fatty acid deficiency, further exacerbating the function
55
56 of neurons and neurological system.⁴⁸
57
58
59
60

1
2
3 Of note, despite children with SMA Type I having Body Mass Index (BMI) scores that correspond with
4 normal or underweight, they also have an increased fat mass index (FMI), placing them in an
5 overweight risk category.¹⁹ Children with SMA Type I may have lower caloric requirements than
6 healthy age-matched peers, increasing risk for over and undernourished states and deficiencies of
7 critical nutrients. Standardized growth charts may overestimate faltering growth in SMA type I.⁴⁸ Due
8 to this contradiction, BMI is considered an insufficient measure of adiposity in patients with SMA.²⁰
9
10 One proposed explanation for this inverse relationship between lower BMI and increased FMI is a
11 discrepancy between energy intake and expenditure, a theory reflected in the disease's progression
12 to immobilization.⁴⁹
13

14
15
16 This physiological phenomenon is further reflected in our respiratory quotient findings collected from
17 indirect calorimetry measurements. Respiratory quotient is a metabolic indicator based on the ratio
18 of the volume of carbon dioxide produced and the oxygen consumed.⁵⁰ Our preliminary findings found
19 a mean respiratory quotient similar to that reported by Bertoli et al (2017), with a RQ of 0.84
20 (0.05SD)¹⁹, which is indicative of undernutrition and would suggest a need to increase total energy
21 intake. This anomaly needs further investigation to ascertain if children with SMA are truly
22 undernourished or whether this is just a reflection of an altered body composition.
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42

43 **Study limitations**

44
45
46 This study is limited by its single centre nature, short duration, observational design without a control
47 group, and small number of participants. Another limitation identified from this pilot study were
48 parents' unwillingness to add carbohydrate or revert to their original enteral feed formula after
49 SMAAF trial. Interestingly, these components of the trial were deemed important by families who
50 were involved in the study planning phase. This deviation from the protocol would make a future
51 randomised cross-over study untenable. Nonetheless, the safety and tolerance of an amino acid
52
53
54
55
56
57
58
59
60

1
2
3 formula with added probiotics in respect to constipation and other gastrointestinal management
4
5 supports the need for further well controlled prospective studies.
6
7

8 **CONCLUSION**

9

10
11 Advances in SMA Type I therapy poses new challenges, particularly in relation to the management of
12
13 gastrointestinal symptoms and liver disorders. Children with SMA Type I who are displaying
14
15 gastrointestinal symptoms such as constipation and reflux may benefit from an amino acid formula
16
17 that is fortified with probiotics. More research into fatty acid metabolism and manipulation of type of
18
19 fats in children with SMA Type I is warranted.
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

REFERENCES

1. Verhaart IEC, Robertson A, Wilson IJ, Aartsma-Rus A, Cameron S, Jones CC, et al. Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy - a literature review. *Orphanet J Rare Dis.* 2017;12(1):124.
2. Kolb SJ, Kissel JT. Spinal Muscular Atrophy. *Neurol Clin.* 2015;33(4):831-46.
3. Yeo CJJ, Darras BT. Overturning the Paradigm of Spinal Muscular Atrophy as Just a Motor Neuron Disease. *Pediatric neurology.* 2020;109:12-9.
4. Pane M, Coratti G, Sansone VA, Messina S, Bruno C, Catteruccia M, et al. Nusinersen in type 1 spinal muscular atrophy: Twelve-month real-world data. *Annals of neurology.* 2019;86(3):443-51.
5. Mendell JR, Al-Zaidy S, Shell R, Arnold WD, Rodino-Klapac LR, Prior TW, et al. Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy. *The New England journal of medicine.* 2017;377(18):1713-22.
6. Sansone VA, Pirola A, Albamonte E, Pane M, Lizio A, D'Amico A, et al. Respiratory Needs in Patients with Type 1 Spinal Muscular Atrophy Treated with Nusinersen. *The Journal of pediatrics.* 2020;219:223-8.e4.
7. Edel L, Grime C, Robinson V, Manzur A, Abel F, Munot P, et al. A new respiratory scoring system for evaluation of respiratory outcomes in children with spinal muscular atrophy type1 (SMA1) on SMN enhancing drugs. *Neuromuscular Disorders.* 2021;31(4):300-9.
8. Li Y-J, Chen T-H, Wu Y-Z, Tseng Y-H. Metabolic and Nutritional Issues Associated with Spinal Muscular Atrophy. *Nutrients.* 2020;12(12):3842.
9. Deguise MO, Baranello G, Mastella C, Beauvais A, Michaud J, Leone A, et al. Abnormal fatty acid metabolism is a core component of spinal muscular atrophy. *Annals of clinical and translational neurology.* 2019;6(8):1519-32.
10. Bowerman M, Swoboda KJ, Michalski JP, Wang GS, Reeks C, Beauvais A, et al. Glucose metabolism and pancreatic defects in spinal muscular atrophy. *Annals of neurology.* 2012;72(2):256-68.
11. Walter LM, Deguise M-O, Meijboom KE, Betts CA, Ahlskog N, van Westering TLE, et al. Interventions Targeting Glucocorticoid-Krüppel-like Factor 15-Branched-Chain Amino Acid Signaling Improve Disease Phenotypes in Spinal Muscular Atrophy Mice. *EBioMedicine.* 2018;31:226-42.
12. Schmitt F, Hussain G, Dupuis L, Loeffler JP, Henriques A. A plural role for lipids in motor neuron diseases: energy, signaling and structure. *Frontiers in cellular neuroscience.* 2014;8:25.
13. Zolkipli Z, Sherlock M, Biggar WD, Taylor G, Hutchison JS, Peliowski A, et al. Abnormal fatty acid metabolism in spinal muscular atrophy may predispose to perioperative risks. *European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.* 2012;16(5):549-53.
14. DiVito D, Konek S. Spinal Muscular Atrophy— Summary for Nutritional Care: The Consensus Statement for Standard of Care in Spinal Muscular Atrophy. *ICAN: Infant, Child, & Adolescent Nutrition.* 2010;2(6):348-54.
15. Corsello A, Scatigno L, Pascuzzi MC, Calcaterra V, Dilillo D, Vizzuso S, et al. Nutritional, Gastrointestinal and Endo-Metabolic Challenges in the Management of Children with Spinal Muscular Atrophy Type 1. *Nutrients.* 2021;13(7).
16. Bertoli S, De Amicis R, Mastella C, Pieri G, Giaquinto E, Battezzati A, et al. Spinal Muscular Atrophy, types I and II: What are the differences in body composition and resting energy expenditure? *Clin Nutr.* 2017;36(6):1674-80.
17. Dangouloff T, Servais L. Clinical Evidence Supporting Early Treatment Of Patients With Spinal Muscular Atrophy: Current Perspectives. *Therapeutics and clinical risk management.* 2019;15:1153-61.
18. Mercuri E, Finkel RS, Muntoni F, Wirth B, Montes J, Main M, et al. Diagnosis and management of spinal muscular atrophy: Part 1: Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care. *Neuromuscul Disord.* 2018;28(2):103-15.

19. Bertoli S, De Amicis R, Mastella C, Pieri G, Giaquinto E, Battezzati A, et al. Spinal Muscular Atrophy, types I and II: What are the differences in body composition and resting energy expenditure? *Clinical nutrition (Edinburgh, Scotland)*. 2017;36(6):1674-80.
20. Watson KS, Boukhloufi I, Bowerman M, Parson SH. The Relationship between Body Composition, Fatty Acid Metabolism and Diet in Spinal Muscular Atrophy. *Brain Sciences*. 2021;11(2):131.
21. Moore G, A L, G M, M R, Z D. Describing nutrition in spinal muscular atrophy: A systematic review. *Neuromuscular Disorders*. 2016;26(7):395-404.
22. Davis RH, Godshall BJ, Seffrood E, Marcus M, LaSalle BA, Wong B, et al. Nutritional practices at a glance: spinal muscular atrophy type I nutrition survey findings. *Journal of child neurology*. 2014;29(11):1467-72.
23. Fried SK, Rao SP. Sugars, hypertriglyceridemia, and cardiovascular disease. *The American Journal of Clinical Nutrition*. 2003;78(4):873S-80S.
24. Van Rompay MI, McKeown NM, Goodman E, Eliasziw M, Chomitz VR, Gordon CM, et al. Sugar-Sweetened Beverage Intake Is Positively Associated with Baseline Triglyceride Concentrations, and Changes in Intake Are Inversely Associated with Changes in HDL Cholesterol over 12 Months in a Multi-Ethnic Sample of Children. *The Journal of nutrition*. 2015;145(10):2389-95.
25. DiStefano JK, Shaibi GQ. The relationship between excessive dietary fructose consumption and paediatric fatty liver disease. *Pediatric obesity*. 2021;16(6):e12759.
26. Jensen T, Abdelmalek MF, Sullivan S, Nadeau KJ, Green M, Roncal C, et al. Fructose and sugar: A major mediator of non-alcoholic fatty liver disease. *Journal of hepatology*. 2018;68(5):1063-75.
27. Huysentruyt K, Koppen I, Benninga M, Cattaert T, Cheng J, De Geyter C, et al. The Brussels Infant and Toddler Stool Scale: A Study on Interobserver Reliability. *Journal of pediatric gastroenterology and nutrition*. 2019;68(2):207-13.
28. Rosen R, Vandenplas Y, Singendonk M, Cabana M, DiLorenzo C, Gottrand F, et al. Pediatric Gastroesophageal Reflux Clinical Practice Guidelines: Joint Recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition. *Journal of pediatric gastroenterology and nutrition*. 2018;66(3):516-54.
29. Russo M, Strisciuglio C, Scarpato E, Bruzzese D, Casertano M, Staiano A. Functional Chronic Constipation: Rome III Criteria Versus Rome IV Criteria. *Journal of neurogastroenterology and motility*. 2019;25(1):123-8.
30. Giannattasio A, Guarino A, Lo Vecchio A. Management of children with prolonged diarrhea. *F1000Res*. 2016;5.
31. Bertoli S, De Amicis R, Bedogni G, Foppiani A, Leone A, Ravella S, et al. Predictive energy equations for spinal muscular atrophy type I children. *Am J Clin Nutr*. 2020;111(5):983-96.
32. Villar J, Cheikh Ismail L, Victora CG, Ohuma EO, Bertino E, Altman DG, et al. International standards for newborn weight, length, and head circumference by gestational age and sex: the Newborn Cross-Sectional Study of the INTERGROWTH-21st Project. *Lancet*. 2014;384(9946):857-68.
33. Cole TJ, Williams AF, Wright CM. Revised birth centiles for weight, length and head circumference in the UK-WHO growth charts. *Annals of human biology*. 2011;38(1):7-11.
34. WHO Child Growth Standards based on length/height, weight and age. *Acta paediatrica (Oslo, Norway : 1992) Supplement*. 2006;450:76-85.
35. Schofield WN. Predicting basal metabolic rate, new standards and review of previous work. *Hum. Nutr. Clin. Nutr.* 39C, S5-S411985. 5-41 p.
36. Yang Y, Vassilakos G, Hammers DW, Yang Z, Barton ER, Sweeney HL. Smooth muscle atrophy and colon pathology in SMN deficient mice. *American journal of translational research*. 2019;11(3):1789-99.

- 1
- 2
- 3
- 4 37. van den Berg MM, Benninga MA, Di Lorenzo C. Epidemiology of Childhood Constipation: A
- 5 Systematic Review. *Official journal of the American College of Gastroenterology | ACG.*
- 6 2006;101(10):2401-9.
- 7 38. Wang CH, Finkel RS, Bertini ES, Schroth M, Simonds A, Wong B, et al. Consensus statement
- 8 for standard of care in spinal muscular atrophy. *Journal of child neurology.* 2007;22(8):1027-49.
- 9 39. Sintusek P, Catapano F, Angkathunkayul N, Marrosu E, Parson SH, Morgan JE, et al.
- 10 Histopathological Defects in Intestine in Severe Spinal Muscular Atrophy Mice Are Improved by
- 11 Systemic Antisense Oligonucleotide Treatment. *PloS one.* 2016;11(5):e0155032-e.
- 12 40. Bach JR. Medical considerations of long-term survival of Werdnig-Hoffmann disease.
- 13 *American journal of physical medicine & rehabilitation.* 2007;86(5):349-55.
- 14 41. Dethlefsen L, Relman DA. Incomplete recovery and individualized responses of the human
- 15 distal gut microbiota to repeated antibiotic perturbation. *Proceedings of the National Academy of*
- 16 *Sciences of the United States of America.* 2011;108 Suppl 1(Suppl 1):4554-61.
- 17 42. Kamphorst K, Van Daele E, Vlieger AM, Daams JG, Knol J, van Elburg RM. Early life antibiotics
- 18 and childhood gastrointestinal disorders: a systematic review. *BMJ Paediatrics Open.*
- 19 2021;5(1):e001028.
- 20 43. Avelar Rodriguez D, Popov J, Ratcliffe EM, Toro Monjaraz EM. Functional Constipation and
- 21 the Gut Microbiome in Children: Preclinical and Clinical Evidence. *Frontiers in Pediatrics.* 2021;8.
- 22 44. Berti B, Onesimo R, Leone D, Palermo C, Giorgio V, Buonsenso D, et al. Hypoglycaemia in
- 23 patients with type 1 SMA: an underdiagnosed problem? *Arch Dis Child.* 2020;105(7):707.
- 24 45. Lehmann S, Ferrie S, Carey S. Nutrition Management in Patients With Chronic
- 25 Gastrointestinal Motility Disorders: A Systematic Literature Review. *Nutrition in Clinical Practice.*
- 26 2020;35(2):219-30.
- 27 46. Keohane PP, Attrill H, Love M, Frost P, Silk DB. Relation between osmolality of diet and
- 28 gastrointestinal side effects in enteral nutrition. *British medical journal (Clinical research ed).*
- 29 1984;288(6418):678-80.
- 30 47. Jadhav HB, Annapure US. Triglycerides of medium-chain fatty acids: a concise review.
- 31 *Journal of Food Science and Technology.* 2022.
- 32 48. Poruk KE, Davis RH, Smart AL, Chisum BS, Lasalle BA, Chan GM, et al. Observational study of
- 33 caloric and nutrient intake, bone density, and body composition in infants and children with spinal
- 34 muscular atrophy type I. *Neuromuscul Disord.* 2012;22(11):966-73.
- 35 49. De Amicis R, Baranello G, Foppiani A, Leone A, Battezzati A, Bedogni G, et al. Growth
- 36 patterns in children with spinal muscular atrophy. *Orphanet journal of rare diseases.* 2021;16(1):375.
- 37 50. Matarese LE. Indirect Calorimetry: Technical Aspects. *Journal of the American Dietetic*
- 38 *Association.* 1997;97(10, Supplement):S154-S60.
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

Figure 1 Timeline to highlight study procedure for children recruited to the Spinal Muscular Atrophy Amino Acid Formula Trial (SMAAF)

Table 1 Comparison of macronutrient composition for the traditional amino acid formula with SMAAF

<u>Nutrient</u>	<u>Traditional AAF</u>	<u>SMAAF</u>
<u>Carbohydrates, %TEI</u>	<u>85</u>	<u>60</u>
<u>Fat, %TEI</u>	<u>5 (of which MCT 0%)</u>	<u>30 (of which MCT 35%)</u>
<u>Protein, %TEI</u>	<u>10</u>	<u>10</u>
<u>Per 100ml</u>		
<u>Probiotics (CTU)</u>	<u>Variable</u>	<u>1 x 220</u>
<u>Prebiotics, g</u>	<u>Nil</u>	<u>1</u>

Abbreviations: TEI; total energy intake. SMAAF; spinal muscular atrophy amino acid formula. AAF; amino acid formula. MCT; medium chain triglycerides

Table 2 The demographic characteristics of all children who changed on to Spinal Muscular Atrophy

Amino Acid Formula (SMAAF)

Characteristic	
Sex, <i>N</i> (%)	
Male	5 (36)
Female	9 (64)
Age in decimal years, mean (SD)	
	4.1 (1.2)
Weight, mean (SD), kg	
	14.8 (1.9)
Weight Z score (SD)	
	-0.7 (0.9)
Height, mean (SD), cm	
	98.0 (8.6)
Height Z score (SD)	
	-0.6 (0.9)
Race/ Ethnicity, <i>N</i> (%)	
White/ White Other	8 (58)
Black African	1 (7)
Asian/ Asian Indian/ Asian other	5 (35)
Ventilation support, <i>N</i> (%)	
Self-ventilating in air	3 (21)
Non-Invasive Ventilation - overnight only	10 (71)
Non-Invasive Ventilation - dependent	1 (8)
Feeding route, <i>N</i> (%)	
Gastrostomy	12 (84)
Gastrostomy with jejunal extension	1 (8)
Naso Gastric Tube	1 (8)
Type of feed, <i>N</i> (%)	
Standard whole protein (1.0 kcal/ ml)	7 (50)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Low energy whole protein (0.7 kcal/ ml)	3 (21)
Hydrolysed Formula (1.0 kcal/ml)	1 (8)
Amino acid without Probiotics	3 (21)

For Peer Review

Table 3 Comparison of baseline resting energy expenditure using different methods

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

	Indirect Calorimetry	Basal Metabolic Rate,	Spinal Muscular Atrophy, mean	P value
	Mean (SD) Kcal/day	mean (SD), kcal/ day ³⁵	(SD), kcal/ day ³¹	
Resting Energy Expenditure, mean (SD) Kcal/ day	803 (103)	789 (90)	840 (114)	0.7
Resting Energy Expenditure, mean (SD), kcal/ kg	51.5 (7)	52.6 (7)	56 (8)	0.1
Respiratory Quotient, N (%)	0.80 (0.05)			

Peer Review

Table 4 Nutrient intake of children on Spinal Muscular Atrophy Amino Acid Formula (SMAAF)

Nutrient Composition	(n=14)
Total feed volume, mean (SD), ml/ day	866 (186)
Concentration of Neocate Syneo, mean (SD), % <i>(Standard concentration of Neocate Syneo 15%)</i>	21.6 (6)
Total energy intake, mean (SD), Kcal/kg	58 (14)
Protein, mean (SD), grams/ kg	1.7 (0.6)
Probiotics Bifidobacterium breve M-16V, Colony Forming Unit (SD)	1 x 1897 (562)
Prebiotics Fibre Oligofructose, mean (SD), grams/ day	8.3 (2.5)
Medium chain triglycerides, mean (SD), grams/ day	13.9 (4.2)

Table 5 Reported change in symptoms after children with SMA Type 1 changed to an Amino Acid Formula (SMAAF)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Gastrointestinal Intolerance	Number of patients with	Number of patients with improved	P value (95% Confidence Interval)
Symptom	symptom	symptoms post switch to SMAAF	
Reflux, <i>N</i> (%)	5/14 (35)	4/5 (80)	
Loose stools, <i>N</i> (%)	1/14 (7)	1/1 (100)	
Constipation, <i>N</i> (%)	12/14 (85)	10/12 (83)	
Of which on,			
Stool softener medication, <i>N</i> (%)	10/12 (83)	8/10 (80)	
Stool consistency, Bristol Stool Chart Category, (SD)	2.2 (0.4)	3.6 (0.4)	0.001 (2.72-3.72)
Stool frequency - bowel movements per week, (SD)	3.6 (1.08)	4.9 (0.45)	0.09 (-0.65-2.0)

Peer Review

Abstract

Background: An increasing number of families of spinal muscular atrophy (SMA) children are incorporating an amino acid-based enteral formula into their child's feeding regimens. Other components of the amino acid-based formula include added carbohydrates, electrolytes, and probiotics. Due to insufficient evidenced based research regarding the efficacy of the formula clinicians are unable to prescribe or endorse. The aim was to assess the tolerability and safety of an adapted version of the traditional SMA amino acid formula (SMAAF) in children with SMA Type I.

Methods: Children with SMA Type I were recruited if exclusively enterally fed and experiencing at least one gastrointestinal symptom (reflux, vomiting, constipation and/ or diarrhoea). Children were transferred on to an amino acid formula (Neocate® Syneo™- Nutricia) for eight weeks. Primary outcome was feed tolerance, measured weekly by telephone consultation to monitor gastrointestinal tolerance.

Results: Fourteen children were recruited, mean age 4.1 years (1.2SD). The mean resting energy expenditure measured by indirect calorimetry was 51kcal/ kg (7SD). The most common gastrointestinal complaint prior to switching to SMAAF was constipation (n=12). Ten of the 12 children who reported constipation symptoms were prescribed stool softeners/laxatives daily and after 8 weeks on SMAAF, 8 of these 10 (80%) children reduced or discontinue stool softener/ laxatives. Parents reported an improvement with reflux symptoms in 4 out of 5 children whilst on SMAAF.

Conclusion: Our pilot study suggests that children with SMA Type I who are displaying gastrointestinal symptoms, such as constipation and reflux may benefit from an amino acid formula.

BACKGROUND

Spinal muscular atrophy (SMA) is the most common genetic cause of mortality in infancy, SMA type I is the most severe form of the disease, accounting for approximately 60% of cases.¹ SMA is characterized by degeneration of brainstem and spinal cord motor neurons that lead to progressive muscle weakness and atrophy.² These neurological changes result in progressive swallowing, feeding and gastrointestinal complications as well as respiratory failure.³

Improvements in standards of care and the advent of new therapeutic approaches have resulted in improvements in survival and functional abilities in these patients, changing the course of the disease.^{4, 5} So far, most of the attention has been focused on survival and motor or respiratory outcome.^{6, 7} Despite feeding being one of the most important aspects in the care of SMA, less has been reported about the possible impact of nutrition in the management of children with SMA type I.⁸

Of note, previous studies have reported more generalised metabolic abnormalities in SMA such as altered fatty acid metabolism, hyperlipidaemia, hyperglycaemia, hyperglucagonemia, increased hepatic insulin sensitivity and glucose intolerance.⁹⁻¹¹ Interestingly, lipid metabolism and fatty acid oxidation defects have been reported in early studies of patients with SMA where increased esterified carnitine and reduced β -oxidation capacity were observed.¹² Such perturbations could directly lead to impaired hepatic function, which is supported by the report of more than one-third of autopsies of children with SMA reveal liver steatosis on post-mortem necropsy.¹³

Current standard of care recommendations highlight the importance of a multidisciplinary approach in the management of SMA Type I which, includes nutrition and feeding as key components.^{14, 15} Progressive muscle atrophy in children with SMA is accompanied with decreased lean body mass, increased fat mass as well as gastrointestinal symptoms such as gastro-oesophageal reflux disease and constipation.¹⁶ Typically, long term nutritional support in the form of a gastrostomy is recommended as soon as oral intake is compromised.¹⁷

1
2
3 Recent studies led by our team working on SMA animal models support an independent and adjuvant
4 role for nutrition in the absence of proactive respiratory care interventions.¹¹ Their data, and clinical
5 experience, suggest a critical role for nutrition on quality of life in children with SMA.¹⁸ The potential
6 benefit of the synergistic effect of a specialised SMA diet and a drug in the management of SMA have
7 been highlighted, which is highly relevant in the present therapeutic landscape.^{19, 20}

8
9
10
11
12
13
14
15 Current dietetic recommendations for children with SMA is based on individual tolerance.^{18, 21}
16
17 However, an increasing number of families of SMA children are incorporating amino acid based enteral
18 formulas into their child's feeding regimens. Originating from North America, the diet was designed
19 and initiated by a SMA parents in the hope of improving SMA symptoms in their child. The diet has
20 grown in popularity over the last few years following positive feedback from parents and individuals
21 living with SMA, mostly via social media outlets.

22
23
24
25
26
27
28
29 Characteristics of the traditional amino acid formula diet (<http://www.aadietinfo.com>) include high
30 carbohydrates, low fats, probiotics, vitamin D, co-enzyme Q10, branched-chain amino acid
31 supplementation and oral hydration solutions. Anecdotally, families have reported improvements in
32 their child's symptoms which are often associated with SMA including airway secretions,
33 drooling, respiratory infections, constipation, and gastroesophageal reflux. Additionally, quality of
34 sleep along with improvements in strength and stamina have also been reported to improve whilst
35 following the SMA amino acid diet.²² However, due to insufficient evidenced based research, clinicians
36 are unable to prescribe or endorse the SMA amino acid diet, particularly in relation to associated risks
37 between a high carbohydrate diet with hypertriglyceridemia^{23, 24} and non-alcoholic fatty liver
38 disease.^{25, 26}

39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
There is a need for a prospective clinical assessment to monitor the impact of an amino acid enteral
formula on the common gastrointestinal symptoms seen in SMA Type I. Working with SMA families,
we devised an adapted version of the traditional SMA amino acid diet. The proposed aim of this study
was to assess the tolerability and safety of an adapted version of the traditional SMA amino acid diet

1
2
3 that contains an amino acid-based formula with added probiotics and additional carbohydrates
4
5 (SMAAF).
6
7

8 **METHODS**

9

10 **Patients**

11
12
13
14 Children were recruited from our specialist tertiary neuromuscular SMA outpatient's clinic between
15
16 June 2021 to May 2022. The inclusion criteria: a diagnosis of SMA Type I; which meant infants were
17
18 aged over six months old; exclusively enterally fed via a feeding tube (meeting at least 90% of total
19
20 energy intake from enteral formula); and experiencing at least one gastrointestinal symptom including
21
22 (definitions outlined below). Exclusion criteria: children without SMA Type I; are meeting less than
23
24 90% of their total energy requirements from an enteral feeding tube.
25
26
27

28
29 The study was approved by the Health Research Authority, Integrated Research Application System
30
31 (IRAS) 21/WS/0074 IRAS 295489. Written informed consent in accordance with universal good clinical
32
33 practice guidelines in accordance with the ethical standards of the Helsinki declaration of 1975 was
34
35 obtained from all parents of participants after discussing the objectives, study design, risks and
36
37 benefits of participation before enrolment into our study.
38
39

40 **Procedure**

41
42
43 SMAAF was a single center prospective study. Recruited children were transferred on to an amino acid
44
45 formula - (Neocate[®] Syneo[™]- Nutricia), which contains 34% medium chain triglycerides, 50%
46
47 carbohydrate, probiotic-bifidobacterium, and prebiotic-fructo-oligosaccharide. SMAAD was followed
48
49 for eight weeks; after two weeks on SMAAF additional carbohydrates (using Maxijul[®] Super Soluble)
50
51 were planned to be supplemented to 60% total energy intake. At the end of the eight-week trial
52
53 children were to revert to their original enteral formula to compare gastrointestinal symptoms for
54
55 another 4 weeks. Families were provided with components of SMAAF and a prescriptive individual
56
57
58
59
60

1
2
3 feed recipe during their outpatient visit. Table 1 highlights the difference in nutrient intake when
4
5 comparing the traditional amino acid formula with SMAAF
6

7
8 Families had two in person meetings at baseline and week eight, with a telephone consultation at
9
10 week four and six to monitor feed tolerance in respect to esophageal reflux, stool consistency and
11
12 frequency (Figure 1). Parents were requested to report symptoms as either: improved, no change or
13
14 worsened.
15

20 **DATA GATHERING**

23 **Anthropometric Measurements**

24
25 Weight (kg) and length (cm) measurements were collected at baseline (before changing to SMAAF)
26
27 and on completion of the 8-week trial. All anthropometric measurements were collected during their
28
29 routine neuromuscular outpatient clinic by trained clinicians using standardized conventional criteria
30
31 and recognized measuring procedures.
32
33

36 **Gastrointestinal Tolerance Monitoring**

37
38 Stool consistency is a central component in the description of normal or altered bowel habit. Physical
39
40 examination of stool can be considered as a proxy measure for stool consistency and refers to the
41
42 shape and apparent texture of the stool, which can be assessed visually. Stool form scales are a
43
44 standardised and inexpensive method of classifying stool into a finite number of categories that can
45
46 be used by families and health care professionals. The Bristol Stool Scale is a visual stool form scale-
47
48 the ideal stool is generally type 3 or 4, easy to pass without being too watery. Type 1 or 2 indicates
49
50 constipation, whereas types 6 and 7 indicate loose stools.²⁷
51
52

53
54 Tolerance and details of stooling patterns were recorded by families in weekly diaries. Descriptions of
55
56 feed tolerance included the following variables:
57
58
59
60

1
2
3 Reflux - defined as parental observation of the passage of gastric contents into the oesophagus
4 causing regurgitation, possetting or vomiting, which leads to troublesome symptoms that affect daily
5 functioning²⁸; constipation – defined as Rome IV Criteria, less than three defecations a week/ painful
6 and hard stools²⁹; persistent loose stools - lasting longer than 14 days, consisting of more than one
7 loose stool a day.³⁰

15 **Oral Mucus Secretion Monitoring**

16
17 Manual mechanical insufflation–exsufflation (cough assist) is the primary mode of airway clearance
18 therapy performed by families. Families were asked to record in their weekly diaries the frequency
19 and duration of their airway clearance individualised program including oral suctioning and mouth
20 wiping for drooling.

27 **Indirect Calorimetry Measurements**

28
29 Indirect calorimetry was measured at baseline and planned to be repeated after eight-weeks on
30 SMAAD (refer to protocol deviation below) to measure resting energy expenditure (REE) and
31 respiratory quotient (RQ). An open-circuit ventilated-hood system calorimetric measurements were
32 made using a portable metabolic cart (Q-NRG+ RMR, COSMED). It measures resting oxygen
33 consumption (V_{O_2}), carbon dioxide production (V_{CO_2}), and respiratory quotient. REE was auto
34 calculated from these parameters using Weir equation. COSMED Indirect calorimetry was calibrated
35 monthly, using a 2-point calibration method based on two separate mixtures of known gas content.³¹

36
37 Indirect calorimetry was completed by either GOC or SQ, with an early morning measurement
38 (between 08:00 and 09:00) collected during the SMA outpatient day clinic, measured after an 8-h
39 overnight fast to eliminate nutrient thermogenesis. The children lay awake, supine on a bed in a
40 thermally neutral environment (24°C) and were distracted by a portable screen to watch cartoons.

56 **Statistical Analysis**

1
2
3 Continuous quantitative data was calculated as mean and standard deviation. Z scores of weight-for-
4 age and length-for-age, were computed based on UK-WHO growth data.^{32, 33 34} The standard Student
5 t-test was used to compare the weight mean Z scores before and after SMAAF. Analysis of variance
6 was used to compare resting energy expenditure between predictive energy equations and indirect
7 calorimetry. P value < 0.05 was required for statistical significance. Statistical analysis was performed
8 with SPSS software (version 23, IBM SPSS Statistics, Armonk, NY, USA)
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

26 **RESULTS**

27
28 Fourteen children were recruited from June 2021 to May 2022, with a mean age of 4.1 years (1.2 SD),
29 of which 64% were female. The mean WAZ at baseline was -0.7 (0.9SD). At recruitment, all 14 children
30 required manual mechanical insufflation–exsufflation at least twice a day, with 11 of 14 (78%)
31 requiring non-invasive ventilation - biphasic positive airway pressure for at least 12 hours. All children
32 were receiving Nusinersen, an approved disease modifying treatment for SMA. Demographic
33 characteristics of the cohort can be found in Table 2.
34
35
36
37
38
39
40
41

42 Most children (50%; 7 of 14) were on a standard 1kcal/ ml whole protein enteral formula prior to
43 trialling SMAAF; whereas, 3 out of 14 (21%) were already on an amino acid formula (without
44 probiotics). A full breakdown of feed formulas can be seen in Table 2. Indirect Calorimetry was
45 measured at the start of the study to assess energy requirements and respiratory quotient. The mean
46 resting energy expenditure was 803 kcal (103 SD), which equated to 51.5 kcal/ kg (7 SD). The mean
47 respiratory quotient was 0.80 (0.05 SD) (Table 3). An analysis of variance was used to compare resting
48 energy requirements between indirect calorimetry measurements and predictive energy equations
49 (Schofield equation³⁵ and Spinal muscular atrophy equation³¹) there was no significant difference
50
51
52
53
54
55
56
57
58
59
60

1
2
3 between values, p value 0.7 and 0.6, respectively (Table 3). A breakdown of key nutritional
4 components of children on SMAAF can be viewed in Table 4.
5
6

7
8 The most common gastrointestinal complaint reported prior to switching to SMAAF was constipation,
9 present in 12 of 14 (85%) children, of which 10 of the 12 (83%) children required daily stool
10 softeners/laxatives were used to help regulate bowel function. Reflux was reported in 5 of 14 (35%)
11 children (Table 4). Within one week of switching to SMAAF families reported a significant
12 improvement in constipation symptoms.
13
14
15
16
17
18

19
20 Eight of the 10 (80%) children who received stool softeners/laxatives saw an improvement in
21 constipation symptoms and either stopped or reduced medication (from daily to prescribed as
22 required). All three children who were previously on standard amino acid formula prior to switch to
23 amino acid formula with added pre and probiotics reported an improvement in stool consistency and
24 frequency.
25
26
27
28
29
30
31

32 Stool consistency (as per Bristol stool chart classification) significantly improved from baseline
33 compared to end of study (week 8) in children who switched to SMAAF; 2.2 (0.4SD) vs 3.6 (0.4SD) $p <$
34 0.001; CI 2.72-3.72, respectively. Similarly, stool frequency (bowel movements per week) increased
35 from baseline compared to end of study (week 8) from 3.6 (1.08SD) vs 4.9 (0.45SD) per week; $p <$ 0.09,
36 CI -0.65-2, respectively.
37
38
39
40
41
42
43

44 Improvements in reflux was seen in 4 of 5 (80%) children, and a reduction in oral secretion was
45 reported in 6 of 14 (43%) children (Table 5). Although some parents reported a reduction in reflux and
46 oral secretion in respect to mouth wiping or mucus volume suctioned whilst receiving SMAAF, this
47 was not captured in parent diaries and warrants further discussion how best to capture this outcome
48
49
50
51

52
53
54 Appropriate weight gain was observed while children were following SMAAF for the eight-week trial
55 (baseline WAZ score: -0.7 [0.9 SD] vs 8-weeks -0.5 [0.7 SD], $p = .03$).
56
57
58

59 **Adverse Events and Amendments to original protocol**

60

1
2
3 No participants experienced any serious adverse events. However, due to improved gastrointestinal
4 symptoms within one week of starting SMAAF, only two families chose to add additional
5 carbohydrates. Therefore, indirect calorimetry was not repeated at the end of the eight-week trial as
6
7 there was no change in macronutrient intake. Furthermore, 12 of the 14 families refused to revert to
8 their original feed formula after the eight-week trial. The two families who did revert to their previous
9
10 formula reported resumption of constipation within one week and requested to restart SMAAF. An
11
12 Amendment category C was submitted to the Health Research Authority to report changes to the
13
14 original protocol: 295489 21SH01-2 17 Jan 2022 reference 143229.
15
16
17
18
19
20
21

22 **DISCUSSION**

23
24 With the development of disease modifying treatments children with SMA Type I are living beyond
25 the previous four to five years life expectancy but continue to be affected by the highest disease
26
27 burden. Our pilot study suggests that children with SMA Type I who are displaying gastrointestinal
28
29 symptoms, especially when constipation is as a key feature of their clinical phenotype, may benefit
30
31 from an amino acid formula.
32
33
34

35
36 It has been reported that 43% of children with SMA Type I suffer from severe constipation, with
37
38 abdominal pain and meteorism reported in 15% and 14%, respectively³⁶. This is significantly higher
39
40 when compared to childhood constipation in the general population, which ranges from 0.7% to 29.6%
41
42 (median 8.9; inter quartile range 5.3–17.4).³⁷ SMAAF, our simplified version of the traditional SMA
43
44 amino acid diet had the most significant impact in children who suffered from constipation and
45
46 required daily medication to regulate their bowel functions.
47
48
49

50
51 The cause of chronic constipation in children with SMA Type I is multifactorial, including reduced
52
53 intake of fibre and fluids, gastrointestinal dysmotility related to a reduced tone and impaired strength
54
55 of abdominal wall muscles.³⁸ Additionally, animal studies have also reported morphological (both
56
57 gross and microscopic structural) changes within the gastrointestinal tract, along with alterations with
58
59
60

1
2
3 the enteric nervous system, resulting in inflammation and subsequent macrophage infiltration of the
4
5 small intestine.³⁹
6
7

8 Our study found an improvement in bowel function and cessation or reduction of constipation related
9
10 medication in children who commenced SMAAD. Our findings are not only supported by the anecdotal
11
12 reports from families but also by Bach et al. (2007) who performed a retrospective chart review and
13
14 caregiver questionnaire on 103 families of children with SMA Type I. Of which, 57 children were on a
15
16 modified amino acid diet, supplemented with B vitamins and minerals, glutamine, carnitine, long-
17
18 chained free fatty acids, and probiotics - Lactobacillus. All the parents of the children using the
19
20 modified amino acid diet reported one or more of the following benefits: decreased abdominal
21
22 distention and constipation, improved oral secretions and reduced perspiration.⁴⁰
23
24
25

26
27 Of consideration, an additional factor that may be contributing to constipation in SMA Type I is the
28
29 chronic and ubiquitous use of prophylactic antibiotics in our cohort; prescribed to protect against
30
31 opportunistic lung infections. Broad-spectrum antibiotics can affect the abundances of 30% of the
32
33 bacteria in the gut community, causing rapid and significant drops in taxonomic richness, diversity,
34
35 and evenness⁴¹. The routine practice of prophylactic antibiotic administration alters gut flora causing
36
37 dysbiosis and may be contributing to the gastrointestinal complications seen in SMA Type I.^{42, 43}
38
39 Parents of children with SMA Type I have been adding probiotics to their child's amino acid diet to
40
41 overcome the side effects of broad-spectrum antibiotics.⁴⁰
42
43
44

45 A controversial component of the traditional SMA amino acid diet is its excessively high carbohydrate
46
47 intake. The high carbohydrate and low-fat composition of the diet is hypothesised to be beneficial for
48
49 children with SMA Type I by re-balancing the aberrant glucose levels, most likely caused by insufficient
50
51 glycogen storage due to reduced muscle mass. Thus, a diet high in carbohydrate is thought to prevent
52
53 hypoglycaemia.⁴⁴ Furthermore, the low-fat content can help with gastric motility and emptying which
54
55 will reduce reflux.⁴⁵ However, excess glucose within the body is converted to triglycerides and stored
56
57 as fat, contributing to total fat mass and hypertriglycaemia.²⁴ Of note, this practice of excessive
58
59
60

1
2
3 glucose intake may increase the risk of developing a fatty liver, a complication already seen in children
4 with SMA.¹³ Furthermore, the addition of carbohydrate module will add to the osmolality which may
5
6 impact stool consistency and frequency ⁴⁶
7
8
9

10 Children with SMA have an inherent underlying liver abnormality, possibly due to abnormal fatty acid
11 metabolism, and decreased stores of glutathione.⁹ The exact mechanism of this fatty acid metabolism
12
13 abnormality in SMA is unknown, but it is suspected to be related to loss of survival motor neuron
14
15 function, correlates with severity of SMA, and is not directly related to a known genetic disorder of
16
17 mitochondrial fatty acid oxidation.²⁰
18
19
20

21
22 It appears that manipulating the type of fat in the diet may improve gastrointestinal symptoms and
23
24 dyslipidaemia.⁸ SMAAF contains 34% Medium Chain Triglycerides (MCTs), MCTs are more easily
25
26 absorbed into the bloodstream from the gastrointestinal tract, unlike most other lipid molecules that
27
28 require a complex process of digestion.⁴⁷ Dietary approaches aimed at modulating fatty acid
29
30 metabolism defects and their subsequent effects on whole-body metabolic health are therefore an
31
32 interesting strategy to improve quality of life of SMA patients.⁸
33
34
35

36 Further studies are needed to determine whether dietary manipulation used in mitochondrial long-
37
38 chain fatty acid oxidation disorders²² can also benefit children with SMA and ameliorate fatty liver
39
40 pathology. However, manipulating the diet without specialist dietetic input may result in nutritional
41
42 deficiencies as identified by Poruk et al., (2012) who monitored types of dietary intake and
43
44 supplementation in children with SMA Type 1 between the first and last visits. The average length of
45
46 time between the first and last visit was 18 months. The number of subjects following the traditional
47
48 SMA amino acid diet increased from the first visit from 18 of 47 (38%) to the last visit to 23 of 34 (68%).
49
50 The most common source of fat supplementation was safflower oil. Children in this study following an
51
52 amino acids diet had a substantially lower percentage of fat intake and thus, lower intake of essential
53
54 fatty acids. This may increase risk for essential fatty acid deficiency, further exacerbating the function
55
56 of neurons and neurological system.⁴⁸
57
58
59
60

1
2
3 Of note, despite children with SMA Type I having Body Mass Index (BMI) scores that correspond with
4 normal or underweight, they also have an increased fat mass index (FMI), placing them in an
5 overweight risk category.¹⁹ Children with SMA Type I may have lower caloric requirements than
6 healthy age-matched peers, increasing risk for over and undernourished states and deficiencies of
7 critical nutrients. Standardized growth charts may overestimate faltering growth in SMA type I.⁴⁸ Due
8 to this contradiction, BMI is considered an insufficient measure of adiposity in patients with SMA.²⁰
9
10 One proposed explanation for this inverse relationship between lower BMI and increased FMI is a
11 discrepancy between energy intake and expenditure, a theory reflected in the disease's progression
12 to immobilization.⁴⁹
13
14

15
16 This physiological phenomenon is further reflected in our respiratory quotient findings collected from
17 indirect calorimetry measurements. Respiratory quotient is a metabolic indicator based on the ratio
18 of the volume of carbon dioxide produced and the oxygen consumed.⁵⁰ Our preliminary findings found
19 a mean respiratory quotient similar to that reported by Bertoli et al (2017), with a RQ of 0.84
20 (0.05SD)¹⁹, which is indicative of undernutrition and would suggest a need to increase total energy
21 intake. This anomaly needs further investigation to ascertain if children with SMA are truly
22 undernourished or whether this is just a reflection of an altered body composition.
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42

43 **Study limitations**

44
45
46 This study is limited by its single centre nature, short duration, observational design without a control
47 group, and small number of participants. Another limitation identified from this pilot study were
48 parents' unwillingness to add carbohydrate or revert to their original enteral feed formula after
49 SMAAF trial. Interestingly, these components of the trial were deemed important by families who
50 were involved in the study planning phase. This deviation from the protocol would make a future
51 randomised cross-over study untenable. Nonetheless, the safety and tolerance of an amino acid
52
53
54
55
56
57
58
59
60

1
2
3 formula with added probiotics in respect to constipation and other gastrointestinal management
4
5 supports the need for further well controlled prospective studies.
6
7

8 **CONCLUSION**

9

10
11 Advances in SMA Type I therapy poses new challenges, particularly in relation to the management of
12
13 gastrointestinal symptoms and liver disorders. Children with SMA Type I who are displaying
14
15 gastrointestinal symptoms such as constipation and reflux may benefit from an amino acid formula
16
17 that is fortified with probiotics. More research into fatty acid metabolism and manipulation of type of
18
19 fats in children with SMA Type I is warranted.
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

REFERENCES

1. Verhaart IEC, Robertson A, Wilson IJ, Aartsma-Rus A, Cameron S, Jones CC, et al. Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy - a literature review. *Orphanet J Rare Dis.* 2017;12(1):124.
2. Kolb SJ, Kissel JT. Spinal Muscular Atrophy. *Neurol Clin.* 2015;33(4):831-46.
3. Yeo CJJ, Darras BT. Overturning the Paradigm of Spinal Muscular Atrophy as Just a Motor Neuron Disease. *Pediatric neurology.* 2020;109:12-9.
4. Pane M, Coratti G, Sansone VA, Messina S, Bruno C, Catteruccia M, et al. Nusinersen in type 1 spinal muscular atrophy: Twelve-month real-world data. *Annals of neurology.* 2019;86(3):443-51.
5. Mendell JR, Al-Zaidy S, Shell R, Arnold WD, Rodino-Klapac LR, Prior TW, et al. Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy. *The New England journal of medicine.* 2017;377(18):1713-22.
6. Sansone VA, Pirola A, Albamonte E, Pane M, Lizio A, D'Amico A, et al. Respiratory Needs in Patients with Type 1 Spinal Muscular Atrophy Treated with Nusinersen. *The Journal of pediatrics.* 2020;219:223-8.e4.
7. Edel L, Grime C, Robinson V, Manzur A, Abel F, Munot P, et al. A new respiratory scoring system for evaluation of respiratory outcomes in children with spinal muscular atrophy type1 (SMA1) on SMN enhancing drugs. *Neuromuscular Disorders.* 2021;31(4):300-9.
8. Li Y-J, Chen T-H, Wu Y-Z, Tseng Y-H. Metabolic and Nutritional Issues Associated with Spinal Muscular Atrophy. *Nutrients.* 2020;12(12):3842.
9. Deguise MO, Baranello G, Mastella C, Beauvais A, Michaud J, Leone A, et al. Abnormal fatty acid metabolism is a core component of spinal muscular atrophy. *Annals of clinical and translational neurology.* 2019;6(8):1519-32.
10. Bowerman M, Swoboda KJ, Michalski JP, Wang GS, Reeks C, Beauvais A, et al. Glucose metabolism and pancreatic defects in spinal muscular atrophy. *Annals of neurology.* 2012;72(2):256-68.
11. Walter LM, Deguise M-O, Meijboom KE, Betts CA, Ahlskog N, van Westering TLE, et al. Interventions Targeting Glucocorticoid-Krüppel-like Factor 15-Branched-Chain Amino Acid Signaling Improve Disease Phenotypes in Spinal Muscular Atrophy Mice. *EBioMedicine.* 2018;31:226-42.
12. Schmitt F, Hussain G, Dupuis L, Loeffler JP, Henriques A. A plural role for lipids in motor neuron diseases: energy, signaling and structure. *Frontiers in cellular neuroscience.* 2014;8:25.
13. Zolkipli Z, Sherlock M, Biggar WD, Taylor G, Hutchison JS, Peliowski A, et al. Abnormal fatty acid metabolism in spinal muscular atrophy may predispose to perioperative risks. *European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.* 2012;16(5):549-53.
14. DiVito D, Konek S. Spinal Muscular Atrophy— Summary for Nutritional Care: The Consensus Statement for Standard of Care in Spinal Muscular Atrophy. *ICAN: Infant, Child, & Adolescent Nutrition.* 2010;2(6):348-54.
15. Corsello A, Scatigno L, Pascuzzi MC, Calcaterra V, Dilillo D, Vizzuso S, et al. Nutritional, Gastrointestinal and Endo-Metabolic Challenges in the Management of Children with Spinal Muscular Atrophy Type 1. *Nutrients.* 2021;13(7).
16. Bertoli S, De Amicis R, Mastella C, Pieri G, Giaquinto E, Battezzati A, et al. Spinal Muscular Atrophy, types I and II: What are the differences in body composition and resting energy expenditure? *Clin Nutr.* 2017;36(6):1674-80.
17. Dangouloff T, Servais L. Clinical Evidence Supporting Early Treatment Of Patients With Spinal Muscular Atrophy: Current Perspectives. *Therapeutics and clinical risk management.* 2019;15:1153-61.
18. Mercuri E, Finkel RS, Muntoni F, Wirth B, Montes J, Main M, et al. Diagnosis and management of spinal muscular atrophy: Part 1: Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care. *Neuromuscul Disord.* 2018;28(2):103-15.

19. Bertoli S, De Amicis R, Mastella C, Pieri G, Giaquinto E, Battezzati A, et al. Spinal Muscular Atrophy, types I and II: What are the differences in body composition and resting energy expenditure? *Clinical nutrition (Edinburgh, Scotland)*. 2017;36(6):1674-80.
20. Watson KS, Boukhloufi I, Bowerman M, Parson SH. The Relationship between Body Composition, Fatty Acid Metabolism and Diet in Spinal Muscular Atrophy. *Brain Sciences*. 2021;11(2):131.
21. Moore G, A L, G M, M R, Z D. Describing nutrition in spinal muscular atrophy: A systematic review. *Neuromuscular Disorders*. 2016;26(7):395-404.
22. Davis RH, Godshall BJ, Seffrood E, Marcus M, LaSalle BA, Wong B, et al. Nutritional practices at a glance: spinal muscular atrophy type I nutrition survey findings. *Journal of child neurology*. 2014;29(11):1467-72.
23. Fried SK, Rao SP. Sugars, hypertriglyceridemia, and cardiovascular disease. *The American Journal of Clinical Nutrition*. 2003;78(4):873S-80S.
24. Van Rompay MI, McKeown NM, Goodman E, Eliasziw M, Chomitz VR, Gordon CM, et al. Sugar-Sweetened Beverage Intake Is Positively Associated with Baseline Triglyceride Concentrations, and Changes in Intake Are Inversely Associated with Changes in HDL Cholesterol over 12 Months in a Multi-Ethnic Sample of Children. *The Journal of nutrition*. 2015;145(10):2389-95.
25. DiStefano JK, Shaibi GQ. The relationship between excessive dietary fructose consumption and paediatric fatty liver disease. *Pediatric obesity*. 2021;16(6):e12759.
26. Jensen T, Abdelmalek MF, Sullivan S, Nadeau KJ, Green M, Roncal C, et al. Fructose and sugar: A major mediator of non-alcoholic fatty liver disease. *Journal of hepatology*. 2018;68(5):1063-75.
27. Huysentruyt K, Koppen I, Benninga M, Cattaert T, Cheng J, De Geyter C, et al. The Brussels Infant and Toddler Stool Scale: A Study on Interobserver Reliability. *Journal of pediatric gastroenterology and nutrition*. 2019;68(2):207-13.
28. Rosen R, Vandenplas Y, Singendonk M, Cabana M, DiLorenzo C, Gottrand F, et al. Pediatric Gastroesophageal Reflux Clinical Practice Guidelines: Joint Recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition. *Journal of pediatric gastroenterology and nutrition*. 2018;66(3):516-54.
29. Russo M, Strisciuglio C, Scarpato E, Bruzzese D, Casertano M, Staiano A. Functional Chronic Constipation: Rome III Criteria Versus Rome IV Criteria. *Journal of neurogastroenterology and motility*. 2019;25(1):123-8.
30. Giannattasio A, Guarino A, Lo Vecchio A. Management of children with prolonged diarrhea. *F1000Res*. 2016;5.
31. Bertoli S, De Amicis R, Bedogni G, Foppiani A, Leone A, Ravella S, et al. Predictive energy equations for spinal muscular atrophy type I children. *Am J Clin Nutr*. 2020;111(5):983-96.
32. Villar J, Cheikh Ismail L, Victora CG, Ohuma EO, Bertino E, Altman DG, et al. International standards for newborn weight, length, and head circumference by gestational age and sex: the Newborn Cross-Sectional Study of the INTERGROWTH-21st Project. *Lancet*. 2014;384(9946):857-68.
33. Cole TJ, Williams AF, Wright CM. Revised birth centiles for weight, length and head circumference in the UK-WHO growth charts. *Annals of human biology*. 2011;38(1):7-11.
34. WHO Child Growth Standards based on length/height, weight and age. *Acta paediatrica (Oslo, Norway : 1992) Supplement*. 2006;450:76-85.
35. Schofield WN. Predicting basal metabolic rate, new standards and review of previous work. *Hum. Nutr. Clin. Nutr*. 39C, S5-S411985. 5-41 p.
36. Yang Y, Vassilakos G, Hammers DW, Yang Z, Barton ER, Sweeney HL. Smooth muscle atrophy and colon pathology in SMN deficient mice. *American journal of translational research*. 2019;11(3):1789-99.

- 1
- 2
- 3
- 4 37. van den Berg MM, Benninga MA, Di Lorenzo C. Epidemiology of Childhood Constipation: A
- 5 Systematic Review. *Official journal of the American College of Gastroenterology | ACG.*
- 6 2006;101(10):2401-9.
- 7 38. Wang CH, Finkel RS, Bertini ES, Schroth M, Simonds A, Wong B, et al. Consensus statement
- 8 for standard of care in spinal muscular atrophy. *Journal of child neurology.* 2007;22(8):1027-49.
- 9 39. Sintusek P, Catapano F, Angkathunkayul N, Marrosu E, Parson SH, Morgan JE, et al.
- 10 Histopathological Defects in Intestine in Severe Spinal Muscular Atrophy Mice Are Improved by
- 11 Systemic Antisense Oligonucleotide Treatment. *PloS one.* 2016;11(5):e0155032-e.
- 12 40. Bach JR. Medical considerations of long-term survival of Werdnig-Hoffmann disease.
- 13 *American journal of physical medicine & rehabilitation.* 2007;86(5):349-55.
- 14 41. Dethlefsen L, Relman DA. Incomplete recovery and individualized responses of the human
- 15 distal gut microbiota to repeated antibiotic perturbation. *Proceedings of the National Academy of*
- 16 *Sciences of the United States of America.* 2011;108 Suppl 1(Suppl 1):4554-61.
- 17 42. Kamphorst K, Van Daele E, Vlieger AM, Daams JG, Knol J, van Elburg RM. Early life antibiotics
- 18 and childhood gastrointestinal disorders: a systematic review. *BMJ Paediatrics Open.*
- 19 2021;5(1):e001028.
- 20 43. Avelar Rodriguez D, Popov J, Ratcliffe EM, Toro Monjaraz EM. Functional Constipation and
- 21 the Gut Microbiome in Children: Preclinical and Clinical Evidence. *Frontiers in Pediatrics.* 2021;8.
- 22 44. Berti B, Onesimo R, Leone D, Palermo C, Giorgio V, Buonsenso D, et al. Hypoglycaemia in
- 23 patients with type 1 SMA: an underdiagnosed problem? *Arch Dis Child.* 2020;105(7):707.
- 24 45. Lehmann S, Ferrie S, Carey S. Nutrition Management in Patients With Chronic
- 25 Gastrointestinal Motility Disorders: A Systematic Literature Review. *Nutrition in Clinical Practice.*
- 26 2020;35(2):219-30.
- 27 46. Keohane PP, Attrill H, Love M, Frost P, Silk DB. Relation between osmolality of diet and
- 28 gastrointestinal side effects in enteral nutrition. *British medical journal (Clinical research ed).*
- 29 1984;288(6418):678-80.
- 30 47. Jadhav HB, Annapure US. Triglycerides of medium-chain fatty acids: a concise review.
- 31 *Journal of Food Science and Technology.* 2022.
- 32 48. Poruk KE, Davis RH, Smart AL, Chisum BS, Lasalle BA, Chan GM, et al. Observational study of
- 33 caloric and nutrient intake, bone density, and body composition in infants and children with spinal
- 34 muscular atrophy type I. *Neuromuscul Disord.* 2012;22(11):966-73.
- 35 49. De Amicis R, Baranello G, Foppiani A, Leone A, Battezzati A, Bedogni G, et al. Growth
- 36 patterns in children with spinal muscular atrophy. *Orphanet journal of rare diseases.* 2021;16(1):375.
- 37 50. Matarese LE. Indirect Calorimetry: Technical Aspects. *Journal of the American Dietetic*
- 38 *Association.* 1997;97(10, Supplement):S154-S60.
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

Figure 1 Timeline to highlight study procedure for children recruited to the Spinal Muscular Atrophy Amino Acid Formula Trial (SMAAF)

Table 1 Comparison of macronutrient composition for the traditional amino acid formula with SMAAF

Nutrient	Traditional AAF	SMAAF
Carbohydrates, %TEI	85	60
Fat, %TEI	5 (of which MCT 0%)	30 (of which MCT 35%)
Protein, %TEI	10	10
Per 100ml		
Probiotics (CTU)	Variable	1 x 220
Prebiotics, g	Nil	1

Abbreviations: TEI; total energy intake. SMAAF; spinal muscular atrophy amino acid formula. AAF; amino acid formula. MCT; medium chain triglycerides

Table 2 The demographic characteristics of all children who changed on to Spinal Muscular Atrophy Amino Acid Formula (SMAAF)

Characteristic	
Sex, <i>N</i> (%)	
Male	5 (36)
Female	9 (64)
Age in decimal years, mean (SD)	4.1 (1.2)
Weight, mean (SD), kg	14.8 (1.9)
Weight Z score (SD)	-0.7 (0.9)
Height, mean (SD), cm	98.0 (8.6)
Height Z score (SD)	-0.6 (0.9)
Race/ Ethnicity, <i>N</i> (%)	
White/ White Other	8 (58)
Black African	1 (7)
Asian/ Asian Indian/ Asian other	5 (35)
Ventilation support, <i>N</i> (%)	
Self-ventilating in air	3 (21)
Non-Invasive Ventilation - overnight only	10 (71)
Non-Invasive Ventilation - dependent	1 (8)
Feeding route, <i>N</i> (%)	
Gastrostomy	12 (84)
Gastrostomy with jejunal extension	1 (8)
Naso Gastric Tube	1 (8)
Type of feed, <i>N</i> (%)	
Standard whole protein (1.0 kcal/ ml)	7 (50)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Low energy whole protein (0.7 kcal/ ml)	3 (21)
Hydrolysed Formula (1.0 kcal/ml)	1 (8)
Amino acid without Probiotics	3 (21)

For Peer Review

Table 3 Comparison of baseline resting energy expenditure using different methods

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

	Indirect Calorimetry	Basal Metabolic Rate,	Spinal Muscular Atrophy, mean	P value
	Mean (SD) Kcal/day	mean (SD), kcal/ day ³⁵	(SD), kcal/ day ³¹	
Resting Energy Expenditure, mean (SD) Kcal/ day	803 (103)	789 (90)	840 (114)	0.7
Resting Energy Expenditure, mean (SD), kcal/ kg	51.5 (7)	52.6 (7)	56 (8)	0.1
Respiratory Quotient, <i>N</i> (%)	0.80 (0.05)			

Peer Review

Table 4 Nutrient intake of children on Spinal Muscular Atrophy Amino Acid Formula (SMAAF)

Nutrient Composition	(n=14)
Total feed volume, mean (SD), ml/ day	866 (186)
Concentration of Neocate Syneo, mean (SD), % <i>(Standard concentration of Neocate Syneo 15%)</i>	21.6 (6)
Total energy intake, mean (SD), Kcal/kg	58 (14)
Protein, mean (SD), grams/ kg	1.7 (0.6)
Probiotics Bifidobacterium breve M-16V, Colony Forming Unit (SD)	1 x 1897 (562)
Prebiotics Fibre Oligofructose, mean (SD), grams/ day	8.3 (2.5)
Medium chain triglycerides, mean (SD), grams/ day	13.9 (4.2)


Table 5 Reported change in symptoms after children with SMA Type 1 changed to an Amino Acid

Formula (SMAAF)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Gastrointestinal Intolerance	Number of patients with	Number of patients with improved	P value (95% Confidence Interval)
Symptom	symptom	symptoms post switch to SMAAF	
Reflux, <i>N</i> (%)	5/14 (35)	4/5 (80)	
Loose stools, <i>N</i> (%)	1/14 (7)	1/1 (100)	
Constipation, <i>N</i> (%)	12/14 (85)	10/12 (83)	
Of which on,			
Stool softener medication, <i>N</i> (%)	10/12 (83)	8/10 (80)	
Stool consistency, Bristol Stool Chart	2.2 (0.4)	3.6 (0.4)	0.001 (2.72-3.72)
Category, (SD)			
Stool frequency - bowel movements per week, (SD)	3.6 (1.08)	4.9 (0.45)	0.09 (-0.65-2.0)

Peer Review



For Peer Review

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60